After ALS flop, Amylyx bought a GLP-1 drug from bankrupt Eiger. Here’s how that fits into its plans

Amylyx pulled its ALS drug from the market earlier this year after a Phase III trial failure.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks